Yahoo · Oct 29, 2026
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.69, marking a +1.24% move from the previous day.
HI
NYSE · HIMS
Hims & Hers Health, Inc.
Healthcare · Medical - Equipment & Services
$25.70
Up+$1.90 (+7.37%)
Updated Nov 4, 2026, 5:26 PM
SID Score
3.0/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 8.28B
- P/E ratio
- 63.9
- Dividend yield
- 0.00%
- 52-week range
- $13.74 – $48.34
- Volume
- 7.43M
- Avg. volume
- 27.1M
Price performance · HIMS
HIMS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
HIMS closed at $25.70 after 21 trading sessions, down 12.79% for the selected period.
- Last close
- $25.70
- Period change
- -12.79%
- Period low
- $25.24
- Period high
- $30.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $25.48 | $26.37 | $25.40 | $25.70 | 7.43M |
| Nov 2, 2026 | $27.97 | $28.49 | $25.145 | $25.24 | 10.79M |
| Oct 30, 2026 | $28.51 | $28.7497 | $26.68 | $27.68 | 10.86M |
| Oct 29, 2026 | $29.26 | $30.13 | $28.66 | $29.67 | 7.52M |
| Oct 28, 2026 | $27.71 | $29.805 | $27.60 | $29.32 | 12.28M |
| Oct 27, 2026 | $27.99 | $28.465 | $27.59 | $27.92 | 7.5M |
| Oct 26, 2026 | $27.51 | $27.94 | $27.22 | $27.59 | 5.76M |
| Oct 23, 2026 | $28.85 | $28.905 | $27.30 | $27.71 | 9.83M |
| Oct 22, 2026 | $28.64 | $29.26 | $27.98 | $29.13 | 8.47M |
| Oct 21, 2026 | $29.38 | $29.92 | $28.85 | $29.21 | 6M |
| Oct 20, 2026 | $28.00 | $30.02 | $27.75 | $29.21 | 10.55M |
| Oct 19, 2026 | $28.49 | $29.00 | $27.53 | $28.15 | 7.49M |
| Oct 16, 2026 | $29.51 | $30.00 | $27.53 | $28.07 | 11.02M |
| Oct 15, 2026 | $26.875 | $29.65 | $26.33 | $29.38 | 16.31M |
| Oct 14, 2026 | $29.26 | $29.6799 | $27.565 | $27.72 | 11.07M |
| Oct 13, 2026 | $29.83 | $30.3822 | $28.7248 | $29.71 | 9.78M |
| Oct 12, 2026 | $30.92 | $31.79 | $30.33 | $30.64 | 8.94M |
| Oct 9, 2026 | $28.34 | $31.4473 | $28.3096 | $30.92 | 16.03M |
| Oct 8, 2026 | $29.20 | $29.62 | $27.49 | $28.06 | 15.06M |
| Oct 7, 2026 | $28.87 | $29.9184 | $28.75 | $29.54 | 5.47M |
| Oct 6, 2026 | $30.08 | $30.08 | $29.07 | $29.47 | 8.8M |
Latest HIMS news
The latest Smart Investors Daily articles mentioning HIMS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HIMS research
Overview
Company profile and research snapshot.
Company profile
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $42.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Truist Securities | Hold | — |
| Aug 21, 2026 | Barclays | Overweight | — |
| Aug 11, 2026 | Morgan Stanley | Equal-Weight | — |
| Aug 11, 2026 | TD Cowen | Hold | — |
| Aug 11, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly (NYSE:LLY) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving. Eli Lilly stock is trading at $1,393, up 8%. Taking a look at the peers, Novo Nordisk (NYSE:NVO) stock is at […]
Yahoo · Oct 28, 2026
HIMS Stock Jumps 5% After HHS Temporarily Clears Compounding Of Six Peptides
HHS said it will not go after state-licensed pharmacies, federal facilities, or licensed doctors for compounding six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
Yahoo · Oct 28, 2026
Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding
Key TakeawaysHims & Hers shares rose 6% today after HHS said it won’t act against qualifying pharmacies compounding six unapproved peptides while it writes a formal rule. Hims has said it’s waiting for final FDA rules before selling peptides still under review, so a launch may not come soon.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
